Constellation to Use BioTrove's RapidFire to Screen for Epigenetic Drug Targets | GenomeWeb
NEW YORK (GenomeWeb News) – Startup drug developer Constellation Pharmaceuticals will use BioTrove’s screening and analysis system to develop new therapeutics using an epigenetics-focused approach, BioTrove said today.
 
Constellation will use BioTrove’s RapidFire mass spectrometry system in its screening efforts aimed at developing drugs that can manipulate histone proteins to alter gene expression.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.